Please login to the form below
Newron Pharma appoints commercial affairs VP
Dennis Dionne brings expertise from J&J and Novartis
Milan, Italy-based Newron Pharmaceuticals has promoted Dennis Dionne to vice president of commercial affairs.
Dionne first joined the CNS and pain specialist in 2015 as executive director of commercial operations, and succeeded Anders Haegerstrand on 1 January.
He brings sales and marketing experience from Johnson & Johnson, and served as franchise marketing director for psychiatry, Parkinson's disease and migraine products at Novartis.
Stefan Weber, chief executive officer of Newron, said: “We sincerely thanks Anders for his loyalty, dedication and commitment to Newron and wish him all the best for his personal and professional future.
“At the same time we welcome Dennis as a new member of Newron's senior management team and are looking forward to continuing to work with him to further develop and execute our global commercial strategy.”
COVID-19 Updates and Daily News
Featured jobs
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
-
Digital project manager
-
Competitive
-
Digital account director
-
Competitive
-
Digital strategist
-
Competitive
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- GSK reveals plans for £400m R&D facility expansion in England
- bluebird bio to restart marketing of Zynteglo in EU after previous suspension
- EU approves bluebird bio’s CALD gene therapy Skysona
- NHS earmarks £340m for new medicines fund to fast-track ‘innovative’ treatments
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The future of work has been just around the corner for some time...
- Investigating the Complexities of the Canadian & Global Health Systems
- Impetus Digital Overview
PMHub
Havas Life Medicom
We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...
Latest intelligence
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
- The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
- Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
- Virtual Speaker Program: A Customer Story
- Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....
